Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06099782 · OUTCOME

Percentage of Participants That Were Satisfied or Dissatisfied With the SC Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) Question 1

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) · Source last updated 2026-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
Not reported
Time frame
Up to approximately Day 106

What was measured

The TASQ SC is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with SC administration, experiences related to administration, convenience, and time. The TASQ SC does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ SC evaluates participants' satisfaction or dissatisfaction with SC administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-SC Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.

Analysis population: The analysis population included all randomized participants who received all three doses of pembrolizumab plus berahyaluronidase alfa SC and all three doses of pembrolizumab IV during the treatment crossover period, and subsequently answered question 1 of the TASQ SC.

Groups in this outcome

Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV

In the Treatment Crossover Period participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles.

Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC

In the Treatment Crossover Period participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV57
Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC61

Reported measurements

Very satisfied
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV71.9Not reportedNot reportedNot reportedNot reported
Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC55.7Not reportedNot reportedNot reportedNot reported
Satisfied
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV26.3Not reportedNot reportedNot reportedNot reported
Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC24.6Not reportedNot reportedNot reportedNot reported
Neither satisfied nor dissatisfied
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV0.0Not reportedNot reportedNot reportedNot reported
Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC11.5Not reportedNot reportedNot reportedNot reported
Dissatisfied
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV1.8Not reportedNot reportedNot reportedNot reported
Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC6.6Not reportedNot reportedNot reportedNot reported
Missing
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV0.0Not reportedNot reportedNot reportedNot reported
Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC1.6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        71.9
      2. group Id
        OG001
        value
        55.7
    title
    Very satisfied
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        26.3
      2. group Id
        OG001
        value
        24.6
    title
    Satisfied
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0.0
      2. group Id
        OG001
        value
        11.5
    title
    Neither satisfied nor dissatisfied
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1.8
      2. group Id
        OG001
        value
        6.6
    title
    Dissatisfied
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0.0
      2. group Id
        OG001
        value
        1.6
    title
    Missing
denoms
  1. counts
    1. group Id
      OG000
      value
      57
    2. group Id
      OG001
      value
      61
    units
    Participants
description
The TASQ SC is a 12-item questionnaire that asks questions regarding different aspects of participants' satisfaction with SC administration, experiences related to administration, convenience, and time. The TASQ SC does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the TASQ SC evaluates participants' satisfaction or dissatisfaction with SC administration. As pre-specified by the sSAP, the percentage of participants was reported for each response to TASQ-SC Question 1 according to level of satisfaction, for each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.
groups
  1. description
    In the Treatment Crossover Period participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles.
    id
    OG000
    title
    Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV
  2. description
    In the Treatment Crossover Period participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles.
    id
    OG001
    title
    Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
param Type
NUMBER
population Description
The analysis population included all randomized participants who received all three doses of pembrolizumab plus berahyaluronidase alfa SC and all three doses of pembrolizumab IV during the treatment crossover period, and subsequently answered question 1 of the TASQ SC.
reporting Status
POSTED
time Frame
Up to approximately Day 106
title
Percentage of Participants That Were Satisfied or Dissatisfied With the SC Method of Administration According to Level of Satisfaction, As Assessed by Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) Question 1
type
SECONDARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice